Ind-Swift Laboratories Ltd
Ind-Swift Laboratories Ltd (INDSWFTLAB) last traded at ₹326, a market capitalisation of ₹2,831 crore, on a P/E of 43.5. Over the past 52 weeks the stock has ranged between ₹87 and ₹351. Ind-Swift Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹191 crore and net profit of ₹25 crore. Figures are as of 25 Aug 2026 and are not real time.
Ind-Swift Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Ind-Swift Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹191 cr, up 24.8% from ₹153 cr a year earlier. Net profit was ₹25 cr, up 177.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 12 | 129 | 138 | 153 | 153 | 151 | 170 | 191 |
| Expenses | 24 | 135 | 147 | 149 | 151 | 147 | 149 | 158 |
| Operating profit | -12 | -7 | -9 | 4 | 1 | 4 | 21 | 33 |
| OPM % | -99% | -5% | -7% | 2.4% | 1.0% | 2.8% | 12% | 17% |
| Other income | 13 | 16 | 220 | 15 | 18 | 22 | -3 | 7 |
| Interest | 0 | 10 | -27 | 1 | 2 | 1 | -2 | 1 |
| Depreciation | 0 | 6 | 7 | 7 | 7 | 9 | 8 | 8 |
| Profit before tax | 1 | -7 | 230 | 10 | 10 | 16 | 12 | 33 |
| Tax % | 31% | -16% | 4% | 17% | 22% | 42% | -26% | 25% |
| Net profit | 0 | -5 | 222 | 9 | 8 | 10 | 15 | 25 |
| EPS (₹) | 0.07 | -0.93 | 36.67 | 1.45 | 0.98 | 1.17 | 1.74 | 2.84 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Ind-Swift Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 891 | 1,039 | 1,207 | 1,281 | 562 | 641 | 665 |
| Operating profit | 183 | 202 | 229 | 252 | -19 | 45 | 60 |
| OPM % | 21% | 19% | 19% | 20% | -3.5% | 7% | 9% |
| Net profit | -3 | -2 | 48 | 421 | 250 | 41 | 57 |
| EPS (₹) | -0.53 | -0.36 | 8.06 | 71.24 | 41.32 | 4.77 | 6.73 |
TTM is the trailing twelve months to the most recent quarter.
Ind-Swift Laboratories Ltd growth and returns
- 10 Years
- 0%
- 5 Years
- -6%
- 3 Years
- -19%
- TTM
- 54%
- 10 Years
- 12%
- 5 Years
- 78%
- 3 Years
- -7%
- TTM
- 195%
- 10 Years
- 24%
- 5 Years
- 38%
- 3 Years
- 45%
- 1 Year
- 237%
- 10 Years
- 3%
- 5 Years
- 6%
- 3 Years
- 6%
- Last Year
- 4%
Ind-Swift Laboratories Ltd shareholding pattern
Promoters held 42.93% at Jun 2026, up from 40.94% at Jun 2025. FIIs 10.70% and DIIs 0.17%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 42.01% | 42.01% | 40.94% | 40.94% | 39.49% | 39.49% | 43.00% | 42.93% |
| FIIs | 0.65% | 0.46% | 3.07% | 4.27% | 14.80% | 14.33% | 13.88% | 10.70% |
| DIIs | 0.94% | 0.94% | 0.91% | 0.91% | 0.68% | 0.68% | 0.00% | 0.17% |
| Public | 56.41% | 56.61% | 55.08% | 53.88% | 45.02% | 45.50% | 43.14% | 46.19% |
| No. of shareholders | 28,883 | 28,752 | 28,117 | 28,709 | 43,780 | 42,121 | 39,222 | 40,881 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Ind-Swift Laboratories Ltd corporate filings
- Announcement under Regulation 30 (LODR)-Earnings Call TranscriptCompany Updatehigh impact
Cruxal's analysis: Ind-Swift Laboratories Limited delivered a strong Q1 FY27, with operating income growing…
Read the full analysis - Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseCompany Updatemedium impact
Cruxal's analysis: Ind-Swift Laboratories has announced a strategic initiative to upgrade its Jammu…
Read the full analysis - Audio recording of earning conference call held on 17.08.2026 on un-audited financial results for the quarter ended 30.06.2026.Company Updatelow impact
Cruxal's analysis: Ind-Swift Laboratories Limited has formally notified the stock exchanges regarding the…
Read the full analysis - Announcement under Regulation 30 (LODR)-Investor PresentationCompany Updatehigh impact
Cruxal's analysis: Ind-Swift Laboratories Limited has demonstrated robust operational momentum in Q1FY27…
Read the full analysis - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationCompany Updatelow impact
Cruxal's analysis: Ind-Swift Laboratories Limited has issued a formal intimation regarding its upcoming…
Read the full analysis - Announcement under Regulation 30 (LODR)-Monitoring Agency ReportCompany Updatelow impact
Cruxal's analysis: The company has filed the Monitoring Agency Report for the quarter ended June 30, 2026…
Read the full analysis - Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseCompany Updatelow impact
Cruxal's analysis: Ind-Swift Laboratories Ltd has filed a press release under Regulation 30 of the SEBI…
Read the full analysis - Statement Of NIL Deviation Or Variation Under Reg. 32Company Updatelow impact
Cruxal's analysis: The company has submitted a statement confirming there was no deviation or variation in…
Read the full analysis - Board Meeting Outcome for OUTCOME OF BOARD MEETING DATED AUGUST 10, 2026Board Meetinghigh impact
Cruxal's analysis: Ind-Swift Laboratories Limited reported a robust performance for the quarter ended June…
Read the full analysis - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationCompany Updatelow impact
Cruxal's analysis: The company has filed a disclosure regarding amendments to its Memorandum and Articles of…
Read the full analysis - Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportAGM/EGMhigh impact
Cruxal's analysis: Ind-Swift Laboratories Limited has received shareholder approval at its Extraordinary…
Read the full analysis - Shareholder Meeting / Postal Ballot-Outcome of EGMAGM/EGMmedium impact
Cruxal's analysis: Ind-Swift Laboratories Limited has received shareholder approval at its Extra-Ordinary…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Ind-Swift Laboratories Ltd
Cruxal reads every Ind-Swift Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.